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Abstract
Introduction: Common variants in genes related to inflammation, innate immunity, epithelial cell function, and
angiogenesis have been reported to be associated with risks for Acute Lung Injury (ALI) and related outcomes. We tested
whether previously-reported associations can be validated in an independent cohort at risk for ALI.
Methods: We identified 37 genetic variants in 27 genes previously associated with ALI and related outcomes. We prepared
allelic discrimination assays for 12 SNPs from 11 genes with MAF.0.05 and genotyped these SNPs in Caucasian subjects
from a cohort of critically ill patients meeting criteria for the systemic inflammatory response syndrome (SIRS) followed for
development of ALI, duration of mechanical ventilation, and in-hospital death. We tested for associations using additive and
recessive genetic models.
Results: Among Caucasian subjects with SIRS (n=750), we identified a nominal association between rs2069832 in IL6 and
ALI susceptibility (ORadj 1.61; 95% confidence interval [CI], 1.04–2.48, P=0.03). In a sensitivity analysis limiting ALI cases to
those who qualified for the Acute Respiratory Distress Syndrome (ARDS), rs61330082 in NAMPT was nominally associated
with risk for ARDS. In terms of ALI outcomes, SNPs in MBL2 (rs1800450) and IL8 (rs4073) were nominally associated with
fewer ventilator-free days (VFDs), and SNPs in NFE2L2 (rs6721961) and NAMPT (rs61330082) were nominally associated with
28-day mortality. The directions of effect for these nominal associations were in the same direction as previously reported
but none of the associations survived correction for multiple hypothesis testing.
Conclusion: Although our primary analyses failed to statistically validate prior associations, our results provide some
support for associations between SNPs in IL6 and NAMPT and risk for development of lung injury and for SNPs in IL8, MBL2,
NFE2L2 and NAMPT with severity in ALI outcomes. These associations provide further evidence that genetic factors in genes
related to immunity and inflammation contribute to ALI pathogenesis.
Citation: O’Mahony DS, Glavan BJ, Holden TD, Fong C, Black RA, et al. (2012) Inflammation and Immune-Related Candidate Gene Associations with Acute Lung
Injury Susceptibility and Severity: A Validation Study. PLoS ONE 7(12): e51104. doi:10.1371/journal.pone.0051104
Editor: Yong-Gang Yao, Kunming Institute of Zoology, Chinese Academy of Sciences, China
Received August 12, 2012; Accepted October 31, 2012; Published December 14, 2012
Copyright:  2012 O’Mahony et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health grants 5RC2HL101779-02 and UL1RR025014. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: MMW serves as an editor of PLOS ONE. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and
materials.
* E-mail: mmwurfel@u.washington.edu
Introduction
Acute Lung Injury (ALI) and it’s more severe manifestation,
Acute Respiratory Distress Syndrome (ARDS) are associated with
high mortality rates among intensive care unit patients [1–4].
Despite multiple clinical trials, no pharmacological agent has been
shown to improve ALI-related outcomes [5]. Failure of these trials
is due, in part, to an incomplete understanding of the key biologic
pathways involved in the development and persistence of ALI in
humans. One approach to identification of the key biologic
pathways in ALI pathogenesis is gene-association studies.
Candidate gene studies in ALI have focused on variation within
pathways thought to be important in ALI pathogenesis including
genes involved in inflammation, immunity, oxidation, coagulation,
angiogenesis, cell growth, endothelial barrier, surfactant function,
and transcription regulation [6]. However, only a subset of
putative ALI risk alleles have been validated in independent
populations [7–11]. Robust associations between candidate gene
polymorphisms and ALI validated in independent populations
could support the development of more accurate models
predicting risk for ALI and provide additional rationale for novel
therapeutic interventions.
In this study, we sought to determine whether previously-
reported associations between variants in genes of immunity,
inflammation, angiogenesis and oxidative stress and risk for
development of ALI or related outcomes, are robust. We used a
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e51104nested case-control study design in a prospective cohort of
critically ill patients with SIRS followed for development of ALI.
Secondary analyses looked at ALI related outcomes in a case-only
design.
Methods
SNP selection
We searched PubMed (www.ncbi.nlm.nih.gov/pubmed/) for
publications reporting associations between genetic variants and
development of ALI and/or ALI related outcomes as of August
2010. A panel of ALI investigators (DSO, BJG, MMW) selected
variants based on strength of prior studies, biological relevance,
and HapMap [12] minor allele frequencies (MAF) of .0.05 in
Caucasians. Variants were then further narrowed to those for
which Taqman
TM allelic discrimination assays could be designed
or that were in high linkage disequilibrium (LD) with another SNP
for which an assay could be prepared. As we were unable to design
a Taqman assay for rs1800795, we used a surrogate SNP,
rs2069832 (pairwise r
2=0.97).
Study population
The cohort used for this study has been previously described
[13]. Briefly, patients admitted to the intensive care unit at
Harborview Medical Center, Seattle, WA (Dec 2006–Dec 2010)
with systemic inflammatory response syndrome (SIRS) were
followed prospectively for development of ALI and related
outcomes such as death and other organ dysfunction. Patients
were categorized as having SIRS if they had three or more of the
following concurrently within a 24 hour period; a) body temper-
ature (,36uCo r.38uC) b) HR.90/min, c) RR.20/min or
were on the vent and had PCO2,32 mmHg, and d)
WBC,4,000/mm
3 or .12,000/mm
3. Exclusion criteria included
trauma, HIV or immunosuppression, neurological injury, current
diagnosis of cancer, and presence of a ‘‘do not resuscitate’’ order.
ALI cases were as defined as per the American-European
Consensus Committee (AECC) criteria for ARDS; presence of a
proximal risk factor for ALI, presence of a PaO2/FiO2 (ratio of
partial pressure of oxygen in arterial blood/fraction of oxygen in
gas delivered) ,300, absence of overt congestive heart failure, and
a chest radiograph with bilateral parenchymal opacities as
adjudicated by three critical care physicians [13]. We further
subclassified cases as ARDS if the PaO2/FiO2 ,200. According
to the recently published Berlin Definition for Acute Respiratory
Distress Syndrome, our definition of ALI would equate to mild,
moderate, or severe ARDS while our definition of ARDS would
equate to moderate and severe ARDS [14]. At-risk patients who
did not meet criteria for development of ALI during the ICU
hospitalization were classified as control subjects. This study was
approved by the University of Washington, Division of Human
Subjects Research.
Genotyping
Genomic DNA was extracted from whole blood samples using
the Puregene DNA Isolation Kit (Qiagen, CA). All SNPs were
genotyped using Taqman-based allelic discrimination assays,
(Applied Biosystems, CA), on a multichannel microfluidics chip
(Fluidigm, CA). Genotyping was carried out per the vendor’s
protocol in a blinded fashion.
Statistical Analysis
We identified differences in demographic variables between ALI
and control subjects using Fisher’s exact test for categorical
variables and Student’s t-test for continuous variables. Observed
genotype frequencies were compared with expected frequencies to
test for deviations from Hardy-Weinberg equilibrium using
Fisher’s exact test. To reduce possible confounding from
population-stratification and racial differences, all analyses were
restricted to Caucasian subjects. As a screen for major population
substructure, we performed principal component analysis (PCA)
using SNP genotypes from 67 SNPs available on our samples and
which were also publically available for HapMap 3 subjects [12].
None of the first 5 PCs associated with case/control status.
We used multivariate logistic regression to estimate the
genotype-specific odds ratio (OR) and 95% confidence interval
(CI) for ALI susceptibility. The genotype associations were
analyzed in both additive and recessive models. Covariates were
chosen a priori based on known effects on risk for ALI development
and mortality and included age, sex, APACHE III score,
comorbidities, smoking status and alcohol abuse. A two sided P
value ,0.05 was considered to be nominally significant in all
analyses. To control for type I error from multiple hypotheses
testing, we used a false discovery rate (FDR) approach setting a
threshold of 0.1 as indicative of corrected significance. FDR was
calculated separately for each association test using the total
number of SNPs tested.
We conducted a sensitivity analysis restricting case and control
subjects to avoid phenotype misclassification. We restricted cases
of ALI to only those qualifying for moderate and severe ARDS by
oxygenation criteria (PaO2/FiO2 ,200) and we restricted at-risk
controls to only subjects who did not have an episode of
hypoxemia (PaO2/FiO2 ,300).
In secondary analyses we tested for associations between
genotypes and ventilator free days (VFDs) using linear regression
and mortality within 28 days using logistic regression, adjusting for
covariates as above.
In a post hoc analysis, and for SNPs with adequate genotyping
data available in prior publications, we completed unadjusted
meta-analyses for genotype associations with ALI risk or mortality
in ALI subjects by combining our results with the published data.
We estimated that, under an additive model, our study would
have adequate statistical power (1-b.0.8) to detect associations of
moderate strength with ALI (relative risk (RR) .1.5) for SNPs
with MAF.0.2. Assuming a recessive model, we would have
adequate power to detect a strong association (RR greater than or
equal to 3) with SNPs having a MAF.0.25. See Figure S2 for a
description of power calculations and the range of power over
varying models, allele frequencies and genotype effect strengths.
Statistical analyses were run using the R statistical package and
SNP and Variation Suite 7
TM (Golden Helix
TM, Bozeman, MT).
Results
Characteristics of the Study Population
We genotyped 879 subjects; 238 subjects who developed ALI
and 641 at-risk control subjects (See Figure 1 for the subject
exclusion flow chart diagram). For analyses, we restricted only to
subjects that met 3 criteria for SIRS (Figure 1). These subjects had
a mean age of 54 (StdDev 616) years, were predominantly male
(63.1%), and were moderately ill with a mean APACHEIII score
of 64.7 (StdDev 625). The baseline characteristics for the study
population and comparisons of co-morbidities and clinical risk
factors for ALI between groups are shown in Table 1. Compared
with subjects who did not develop ALI, ALI cases were of similar
age, more likely to be male, and had higher APACHE III scores.
The proportion of subjects with coexisting end-stage renal disease,
liver failure, alcohol abuse, and shock was greater in the ALI
group. Hospital mortality for subjects with ALI was 24.6% which
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would be expected, ALI cases were more likely to have acute
kidney injury, sepsis, shock and fewer VFDs.
SNPs selected for validation
We searched PubMed for gene association studies of ALI and
ARDS susceptibility and related outcomes. At the time of the
search (August, 2010), we identified 37 genetic variants in 27 genes
including SNPs, insertion/deletions, and SNP haplotypes (Table
S1). The set of SNPs selected for this validation study tagged
unique linkage disequilibrium bins that have been associated with
ALI risk and/or ALI related outcomes and were located in or near
the candidate genes. See Table 2 for the list of SNPs used in this
study.
Genotyping results
We achieved genotype call rates across all subjects of over 99%
for each of the 12 SNPs. One of the SNPs, rs4444903, had
genotype frequencies for the control subjects that deviated from
predicted frequency under Hardy Weinberg equilibrium (HWE).
The remaining SNPs had genotype results for the control subjects
that were not significantly different from HWE predictions using
the x
2 test.
We did not observe strong evidence of population stratification
by PCA comparing 67 shared genotypes among our subjects and
HapMap3 subjects. When plotting PC1 vs. PC2, our subjects
clustered with HapMap CEU and TSI subjects but not with Asian
or African clusters as expected. No subject outliers or associations
between phenotype and eigenvalue were observed. See Figure S1.
Association between SNPs and development of ALI
Genotype frequencies for control and case subjects are
presented in Table 3. The A allele of rs4444903 in EGF was
over-represented in cases but genotype frequencies for this SNP in
controls deviated from HWE.
In analyses adjusted for age, gender, APACHEIII score,
presence of diabetes mellitus, end stage renal disease, chronic
alcohol use, cirrhosis and smoking status, we identified a nominal
association between the A allele of rs2069832 in IL6 by recessive
modeling (ORadj 1.61; 95% confidence interval [CI], 1.04–2.48,
P=0.03) (Table 4). The direction of effect and magnitude of the
odds ratio result was consistent with the prior publication [17].
However, this association result did not meet our predetermined
threshold for FDR (FDR,0.1). We did not observe any other
significant associations with ALI susceptibility for any of the
remaining SNPs in adjusted (Table 4) or unadjusted analyses
(Table 3).
We evaluated whether we could complete meta-analyses by
combining our genotype results with the previously published
results but found that the many of the publications lacked
adequate genotyping results details. However, we were able to
complete meta-analyses for several of the SNPs including in
NAMPT, VEGF, IL8, MBL2 and TNF. In unadjusted genotype
association meta-analyses using additive modeling, we observed an
association between rs59744560 in NAMPT and increased risk for
ALI (OR 1.33 (95% CI 1.14–1.56) p value ,0.0003) and an
association between rs61330082 in NAMPT and decreased risk for
Figure 1. Flow diagram for Study design. Subjects with suspected
systemic inflammatory response syndrome (SIRS), n=1327, were
enrolled at Harborview Medical Center (HMC), Seattle, WA during the
period December 2006–December 2010. In this study, we excluded
non-Caucasian subjects, subjects who were found to have previous
enrollment or missing data, and subjects that did not meet 3 SIRS
criteria present concurrently within a 24 hour period.
doi:10.1371/journal.pone.0051104.g001
Table 1. HMC SIRS cohort population characteristics.
All subjects ALI Cases At risk Controls P value
Subjects n 750 224 526
Age, yrs, (IQR) 54 (45–64) 55 (44–66) 54 (44–64) 0.381
Male (%) 480 (64) 159 (71) 321 (61) 0.007
Caucasian, % 100 100 100
ARDS 126 (16.8) 126 (56.3) 0
APACHE III* 64.7625 79625 63624 ,0.001
ALI risk factor
Sepsis 533 (71) 195 (87) 342 (65) ,0.001
Pneumonia 180 (24) 87 (39) 89 (17) ,0.001
Aspiration 90 (12) 49 (22) 42 (8) ,0.001
Transfusion 16 (2.1) 8 (3.6) 8 (1.5) 0.096
Comorbidities
Diabetes 203 (27) 56 (25) 142 (27) 0.65
ESRD 18 (2.4) 3 (1.3) 15 (2.9) 0.30
Liver failure 90 (10.2) 35 (14.7) 55 (8.6) 0.08
Alcohol 263 (35) 94 (42) 168 (32) 0.015
COPD 143 (19) 40 (18) 100 (19) 0.75
CHF 83 (11) 31 (14) 47 (9) 0.06
Smoking 450 (60) 146 (65) 300 (57) 0.062
Outcomes
VFD 19.3610 13611 22610 ,0.001
Death 120 (16) 56 (25) 63 (12) ,0.001
AKI 632 (84) 204 (91) 428 (81) ,0.001
Hemodialysis 53 (7) 25 (11) 32 (6) 0.013
Data is presented as mean 6 SD for continuous variables and n (%) for
categorical variables. P values represent results of t test comparison for
difference of means for continuous variables and Fisher’s exact test for
frequency counts for categorical variables. IQR, interquartile range; VFD,
ventilator free days; AKI, presence of acute kidney injury by AKIN score ./=1
with lowest creatinine during hospitalization used as baseline; Death, subject
death within 28 days of admission.
doi:10.1371/journal.pone.0051104.t001
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observe associations between SNPs in VEGF, IL8, MBL2 or TNF
and ALI risk in this meta-analysis. See Table S3.
Association between SNPs and development of
moderate or severe ARDS
We performed a sensitivity analysis excluding subjects with a
higher likelihood for phenotypic misclassification as suggested by
prior reports [13,18]. We compared controls (n=288) without
hypoxemic respiratory failure and cases with the more severe lung
injury phenotypes, moderate and severe ARDS, n=126. We
identified a nominal association between rs61330082 in NAMPT
and reduced ARDS susceptibility (ORadj 0.61; 95% confidence
interval [CI], 0.40–0.95, P=0.02) which replicates the direction of
effect seen previously for this SNP [19]. We observed trends
toward increased ARDS risk for homozygous carriers of
rs6721961 in NFE2L2 (ORadj 3.83; 95% confidence interval
[CI], 0.93–15.7), and rs2069832 in IL6 (ORadj 1.91; 95%
confidence interval [CI], 0.96–3.40) (Table 5). None of the other
SNPs were associated with ARDS risk in this sensitivity analysis.
Associations with mortality and ventilator free-days
Several of the SNPs selected for this study were previously
associated with ALI-related outcomes [17,20,21]. In secondary
analyses, we tested the 12 SNPs for associations with 28 day
mortality and VFD among subjects with ALI. Genotype frequen-
cies for survivors and non-survivors of ALI are presented in Table
S2. We observed nominal associations between rs4073 in IL8 and
rs1800450 in MBL2 and decreased VFD in adjusted analyses
(Table 6). We also observed nominal associations between
rs61330082 in NAMPT and rs6721961 in NFE2L2 and increased
risk for mortality when using a recessive model (Table 7). Neither
of these associations met our pre-test threshold for significance by
FDR. Using genotype data included in published studies, we
combined our data and the published data to complete meta-
analyses for the SNPs in TNF and MBL2. In an unadjusted
genotype association meta-analysis using recessive modeling,
rs1800629 in TNF was associated with increased mortality (OR
4.6 (95% CI 1.4–14.9), p value 0.001) and rs1800450 inMBL2
displayed a trend toward increased risk (OR 3.07 (95% CI 0.99–
9.5), p value 0.07). See Table S4.
Discussion
At the time of our study, candidate gene association studies had
identified more than 30 genetic variants in over 27 genes that
associate with risk for ALI or ALI-related outcomes. These
associations provide evidence that genetic factors contribute to
ALI and strengthen the link between these specific genes in disease
pathogenesis. In this study, we sought to identify robust
associations between previously-associated genetic variants and
risk for ALI and related outcomes. Using a nested case-control
study in a well-phenotyped ICU cohort, we compared SIRS
subjects who remained at-risk for ALI to those who developed
ALI. Although, in the primary multivariable analyses, the
significance levels for the associations with ALI did not survive
correction for multiple comparisons, our nominal association
results provide some support for prior findings. We observed a
nominal association between a SNP in IL6 (rs2069832, surrogate
for rs1800795) and risk for ALI. In analyses restricting case and
control definitions to minimize misclassification, we observed a
nominal association between rs61330082 in NAMPT and reduced
risk for moderate and severe ARDS consistent with previous
reports [19]. In terms of ALI-related outcomes, we observed
nominal associations between rs4073 in IL8 and rs1800450 in
MBL2 and decreased VFDs. We observed nominal associations
between rs61330082 in NAMPT and rs6721961 in NFE2L2 and
increased 28-day mortality. None of the associations observed in
the secondary analyses survived correction for multiple hypothesis
testing.
IL6 and IL8 have been extensively studied as important
proinflammatory mediators in ALI. Elevated levels of IL-6 and
IL-8 are associated with development of ALI, and persistence of
Table 2. Genetic variants studied.
GENE SNP MAF* Effect Case** Control** Reference
ANGPT2 (Angiopoietin-2) rs2515475 0.14 q risk ARDS EA 449 1080 at risk Su et al, 2009 [33]
EGF (Epidermal growth factor) rs4444903 0.39 q risk ARDS EA 416 1052 at risk Shue et al, 2009 [34]
IL6 (Interleukin-6) rs1800795 0.47 q mortality in ARDS EA; 96 88 at risk; 174
healthy
Marshall et al, 2002 [17]
IL6 (Interleukin-6) rs1800795 haplotypes q risk ARDS [11,29,30]
IL8 (Interleukin-8) rs4073 0.40 q days on MV, q IL8
levels
EA; 23 74 at risk Hildebrand et al, 2007 [20]
IL10 (Interleukin-10) rs1800896 0.47 q risk ARDS EA; 211 429 at risk Gong et al, 2006 [35]
MBL2 (Mannose-binding Lectin 2) rs1800450 0.15 q risk ARDS EA; 212 412 at risk Gong et al, 2007 [36]
NFE2L2 (Nuclear factor, erythroid-
derived, 2-like 2)
rs6721961 0.06 q risk ARDS EA,AA; 30 60, matched case
control
Marzec et al, 2007 [8]
NAMPT (Pre-B cell Colony-
enhancing factor 1)
rs59744560, rs61330082 0.16, 0.33 q risk ARDS; Q risk
ARDS
EA; 87 100 at risk Ye et al, 2005 [19]
SFTPB (Surfactant. protein B) rs1130866 0.43 q risk ARDS EA,AA; 12 390 at risk Quasney et al, 2004 [37]
TNF (Tumor necrosis factor a) rs1800629 0.17 q mortality in ARDS EA 237 476 at risk Gong et al, 2005 [21]
VEGFA (vascular endothelial
growth factor A)
rs3025039 0.19 q risk ARDS EA 117 137 at risk; 103
healthy
Medford et al, 2005 [38]
*MAF, minor allele frequency in the HapMap;
**CEU population; EA, European American; AA, African American; Number refers to number of subjects in group of the referenced study.
doi:10.1371/journal.pone.0051104.t002
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rs1800795 is a promoter SNP that results in decreased expression
of IL-6, and multiple disease associations have been reported for
this SNP [25]. Similarly, rs4073 in IL8 is a promoter SNP that
affects gene transcription and has multiple published disease
associations [26–28]. Our study employed a larger carefully-
phenotyped ICU population as compared to the prior published
studies for genetic risk associations between these genes and ALI.
The CC genotype of rs1800795 in IL6 which results in lower
promoter activity was previously associated with reduced mortality
in ARDS but not with risk for ALI [17]. Nonas et al. observed that
a 3-SNP haplotype in IL6 that included the C allele of rs1800795
was actually associated with reduced risk of ALI [29]. In a
subsequent publication, Flores et al. tested 14 SNPs across IL6
tagging all common linkage disequilibrium bins and found that
none of these SNPs demonstrated an association with ALI.
However, they did find that carriage of two copies of a 6-SNP
haplotype that included the G allele at rs1800795 was associated
with an OR of 2.73 (95% CI, 2.39–5.37) for development of ALI
[11]. Finally, Sutherland et al. reported that carriage of 2 copies of
an IL6 haplotype clade that included the G allele of rs1800795 was
associated with increased risk of death and fewer days alive and
free of ALI [30]. Here we now report that a surrogate for
rs1800795 (rs2069832, r
2=0.98), is associated with increased risk
for ALI and, similar to the studies by Flores and Sutherland, the
effect was best modeled assuming a recessive effect. The SNP in
IL8 was previously associated with increased days on mechanical
ventilation [20]; in our study, rs4073 in IL8 was similarly
Table 4. Associations with ALI susceptibility.
ADDITIVE RECESSIVE
Predictor Odds Ratio
OR Conf.
Interval P-Value FDR Odds Ratio
OR Conf.
Interval P-Value FDR
SFTPB rs1130866 0.93 0.73–1.18 0.55 0.72 0.83 0.56–1.23 0.35 0.90
MBL2 rs1800450 0.98 0.71–1.36 0.90 0.98 1.20 0.43–3.34 0.73 1.00
TNF rs1800629 0.99 0.71–1.38 0.95 0.95 0.56 0.16–2.03 0.36 0.79
IL10 rs1800896 1.09 0.86–1.38 0.49 0.80 1.03 0.70–1.53 0.87 1.00
IL6 rs2069832 1.08 0.85–1.38 0.53 0.76 1.61 1.04–2.48 0.03 0.43
ANGPT2 rs2515475 0.85 0.59–1.38 0.38 0.70 0.66 0.18–2.43 0.52 0.85
VEGF rs3025039 0.84 0.60–1.19 0.34 0.73 0.84 0.24–2.89 0.78 1.00
IL8 rs4073 1.13 0.90–1.43 0.30 0.79 1.29 0.87–1.92 0.21 0.90
EGF rs4444903 0.80 0.62–1.03 0.08 0.55 1.33 0.85–2.07 0.21 0.70
PBEF1 rs59744560 1.26 0.91–1.74 0.17 0.57 1.08 0.39–3.02 0.89 0.96
PBEF1 rs61330082 0.82 0.62–1.07 0.14 0.62 0.99 0.52–1.89 0.99 0.99
NFE2L2 rs6721961 1.11 0.77–1.58 0.58 0.69 2.22 0.68–7.25 0.20 1.00
Multivariate logistic regression adjusted for age, sex, APACHE III score, alcohol abuse, smoking status, and history of chronic renal failure and diabetes mellitus.
doi:10.1371/journal.pone.0051104.t004
Table 5. Associations with moderate or severe ARDS susceptibility.
ADDITIVE RECESSIVE
Predictor Odds Ratio
OR Conf.
Interval P-Value FDR Odds Ratio
OR Conf.
Interval P-Value FDR
SFTPB rs1130866 1.05 0.73–1.51 0.80 0.87 0.85 0.46–1.55 0.59 0.70
MBL2 rs1800450 0.86 0.54–1.37 0.52 0.75 0.69 0.17–2.79 0.60 0.64
TNF rs1800629 0.87 0.53–1.43 0.58 0.76 0.49 0.09–2.63 0.40 0.74
IL10 rs1800896 1.29 0.92–1.8 0.14 0.94 1.23 0.70–2.16 0.47 0.77
IL6 rs2069832 1.22 0.85–1.74 0.28 0.90 1.81 0.96–3.40 0.068 0.44
ANGPT2 rs2515475 0.92 0.56–1.50 0.74 0.87 0.65 0.13–3.15 0.58 0.75
VEGF rs3025039 0.74 0.45–1.23 0.24 1.00 1.01 0.21–4.87 0.99 0.99
IL8 rs4073 1.20 0.85–1.68 0.29 0.76 1.57 0.88–2.80 0.13 0.41
EGF rs4444903 0.87 0.61–1.25 0.45 0.74 1.36 0.71–2.60 0.35 0.77
NAMPT rs59744560 1.06 0.65–1.74 0.81 0.81 0.24 0.04–1.67 0.11 0.49
NAMPT rs61330082 0.62 0.40–0.95 0.02 0.30 0.71 0.24–2.08 0.52 0.75
NFE2L2 rs6721961 1.27 0.79–2.06 0.33 0.72 3.83 0.94–15.6 0.066 0.86
Multivariate logistic regression adjusted for age, sex, APACHE III score, alcohol abuse, smoking status, and history of chronic renal failure and diabetes mellitus. n=414
(126 with ARDS).
doi:10.1371/journal.pone.0051104.t005
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PLOS ONE | www.plosone.org 6 December 2012 | Volume 7 | Issue 12 | e51104associated with reduced days alive and free of ventilation. These
data suggest that common variants in inflammatory cytokines
contribute to disease pathogenesis among subjects at risk for or
who have ALI.
NAMPT (PBEF1) has been associated with lung injury
pathogenesis in recent translational and genetic association studies.
Pre-B-cell colony-enhancing factor (PBEF) is a cytokine encoded
by the gene NAMPT and that has been shown to be present at
higher concentrations in serum and BALF from patients with ALI
[19]. Two studies have reported associations between SNPs in
NAMPT and development of ALI. Ye et al. identified 11 SNPs in
NAMPT and, in a comparison between ALI cases and healthy
controls, demonstrated that two of the SNPs in the promoter
region, T-1001G (rs59744560) and C-1543T (rs61330082) were
associated with risk for sepsis and ALI [19]. A second study using a
nested case-control design in a larger population replicated the
association with the 21001G allele and increased risk for ALI
while the 21543T allele was associated with decreased risk for
ARDS [9]. In our study, we observed the same effect of reduced
risk of ALI for carriers of the 21543T genotype in sensitivity
analyses restricting to cases with ARDS and controls without
hypoxemia. On the other hand, we did not replicate the risk
association for the 21001G SNP (rs59744560) in our primary
adjusted analysis. In a post hoc meta-analysis combining our data
and published genotype data for rs59744560, we did observe a
strongly significant association with risk for ALI. Taken together,
these findings support a role for NAMPT in ALI pathogenesis and
suggest that NAMPT promoter variants are associated with risk for
disease development.
NFE2L2 is a gene that has been identified as a potential
mediator of hyperoxia-induced lung damage via linkage analysis
and positional cloning in mice [31]. NFE2L2 is a transcription
factor that targets antioxidant response elements (AREs) leading to
gene regulation that is protective in the setting of oxidative stress.
Resequencing of NFE2L2 identified a variant (rs6721961) that
resulted in diminished promoter activity in an in vitro transfection
experiment [8]. The authors also reported that rs6721961 was
associated with increased risk for development of trauma-
associated acute lung injury. We observed a trend for association
of this variant with increased risk for ALI among subjects with
SIRS, with a stronger trend in the sensitivity analysis with ARDS
as the outcome. Our analysis resulted in a strong odds ratio for
increased risk for developing ALI similar to the prior report [8].
Misclassification of ALI, particularly the inclusion of subjects
without true ALI among cases, can lead to significant reductions in
statistical power to detect true genetic associations [32]. For
example, a recent study found that removal of subjects with
equivocal CXR results from a set of patients classified with ALI
resulted in an improvement in the strength of associations
observed [18]. We undertook a sensitivity analysis to determine
Table 6. Associations with VFDs.
ADDITIVE RECESSIVE
Predictor Slope
P-
value FDR Slope P-value FDR
SFTPB rs1130866 0.07 0.94 0.94 0.09 0.96 0.96
MBL2 rs1800450 20.43 0.75 0.97 210.25 0.0149 0.19
TNF rs1800629 21.00 0.48 1.00 22.07 0.70 0.91
IL10 rs1800896 20.32 0.75 1.00 21.03 0.52 0.96
IL6 rs2069832 0.78 0.41 1.00 1.03 0.55 0.89
ANGPT2 rs2515475 20.73 0.64 1.00 4.32 0.47 1.00
VEGF rs3025039 21.53 0.28 1.00 21.95 0.70 0.83
IL8 rs4073 20.70 0.47 1.00 23.73 0.0196 0.13
EGF rs4444903 20.82 0.38 1.00 22.93 0.10 0.43
NAMPT rs59744560 0.46 0.73 1.00 1.11 0.79 0.86
NAMPT rs61330082 20.22 0.84 0.91 22.25 0.39 1.00
NFE2L2 rs6721961 0.36 0.80 0.95 23.16 0.50 1.00
Multivariate linear regression adjusted for age, sex, APACHE III score, alcohol
abuse, smoking status, and history of chronic renal failure and diabetes mellitus.
n=224.
doi:10.1371/journal.pone.0051104.t006
Table 7. Associations with 28-day ALI-related mortality.
ADDITIVE RECESSIVE
Predictor Odds Ratio
OR Conf.
Interval P-Value FDR Odds Ratio
OR Conf.
Interval P-Value FDR
SFTPB rs1130866 0.91 0.55–1.50 0.71 1.00 0.73 0.30–1.73 0.46 0.80
MBL2 rs1800450 1.02 0.52–2.01 0.96 0.96 1.74 0.27–11.3 0.57 0.76
TNF rs1800629 0.65 0.31–1.34 0.23 0.76 6.00 0.41–87.2 0.17 0.67
IL10 rs1800896 0.81 0.48–1.35 0.42 0.78 0.80 0.35–1.83 0.60 0.72
IL6 rs2069832 0.96 0.59–1.58 0.88 1.00 0.94 0.39–2.26 0.89 0.97
ANGPT2 rs2515475 1.12 0.50–2.5 0.78 1.00
VEGF rs3025039 1.27 0.62–2.60 0.52 0.84 1.11 0.09–14.5 0.93 0.93
IL8 rs4073 1.01 0.62–1.66 0.95 1.00 1.49 0.67–3.31 0.33 0.79
EGF rs4444903 1.36 0.84–2.21 0.21 1.00 1.79 0.75–4.26 0.19 0.58
NAMPT rs59744560 1.46 0.77–2.80 0.25 0.66 2.26 0.32–15.8 0.43 0.85
NAMPT rs61330082 1.42 0.82–2.45 0.22 0.94 4.37 1.36–14.1 0.016 0.20
NEF2L2 rs6721961 1.40 0.68–2.88 0.37 0.80 9.73 1.27–74.8 0.030 0.18
Multivariate logistic regression adjusted for age, sex, APACHE III score, alcohol abuse, smoking status, and history of chronic renal failure and diabetes mellitus. n=224
(49 non-survivors at 28 days).
doi:10.1371/journal.pone.0051104.t007
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potential misclassification of ALI cases and at-risk controls. We
restricted cases to only those ALI cases qualifying for ARDS
(PF,200) while also restricting control subjects to those who did
not have hypoxemia. This approach reduced the analysis sample
size but resulted in associations with effects that were farther from
the null for the SNPs in IL6, NAMPT and NFE2L2. While these
findings did not achieve statistical significance after correction for
type I error they provide support for the contention that
phenotypic misclassification is a major issue reducing power and
precision in case-control studies of ALI.
Overall, our study failed to demonstrate robust associations
between the SNPs studied and risk for ALI and related outcomes.
Reasons for lack of validation include inadequate statistical power,
misclassification of subject phenotypes, sample population differ-
ences compared to the prior studies, population substructure, and
absence of true association with ALI. As power was limiting to
identify small effect sizes, especially in the recessive model, we
cannot exclude the possibility that we failed to observe true
associations between the SNPs and ALI susceptibility and related
outcomes. A limited analysis on 67 genotypes demonstrated that
subjects from our cohort clustered with HapMap CEU and TSI
subjects suggesting that there was not obvious evidence for cryptic
admixture. However, more subtle differences in population
substructure could have also have affected our ability to detect
true associations. Finally, most of the SNPs included in this study
have not been definitively shown to have functional significance
and may merely serve as markers for causal variants. Future work
will require more dense genotyping or sequencing at these loci to
gain further insight into potential mechanisms.
This study used a well-phenotyped cohort of ICU subjects with
SIRS and a nested-case control design to replicate ALI risk
associations for several previously identified genetic variants. We
observed nominal associations for between SNPS in IL6 and
NAMPT, and risk for ALI and ARDS, but these associations failed
to meet significance after adjusting for multiple comparisons.
Nominal associations were also identified between SNPs in IL8,
MBL2, NAMPT and NFE2L2 and ALI severity outcomes, namely
VFDs and 28-day mortality. The failure to replicate the majority
of ALI risk and outcome associations with statistical significance
emphasizes the challenges of genetic association studies in critical
care populations including sample size and disease classification.
Our results also highlight the importance of independent
confirmatory studies of associations with ALI susceptibility and
related outcomes in order to support a better understanding of
ALI pathogenesis and prognosis.
Supporting Information
Figure S1 Genotype principal component analysis plot
demonstrating overlap of our subjects with HapMap
ethnic populations. Population stratification was assessed by
PCA for 67 shared genotypes among our subjects and HapMap 3
subjects [12]. Our subjects overlapped with CEU and TSI
HapMap subjects but separated from subjects of African or Asian
ethnicity when plotting eigenvalues 1 versus 2.
(TIF)
Figure S2 Plot of power estimates based on minor allele
frequency and genotype effect size. Using CaTS [39], we
generated results for estimated statistical power (1-b.0.8) to detect
additive and recessive model associations over varying allele
frequencies and genotype relative risks, using our known sample
size and case frequency and an alpha error rate of 0.05. Each line
represents a genotype relative risk: A, power estimates for the
additive model for genotype relative risks of 1.25, 1.5, 1.75 and 2;
B, power estimates for the recessive model for genotype relative
risks of 1.5, 2, 2.5 and 3.
(TIF)
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quency analysis for ALI survivors vs. non-survivors at 28
days.
(DOCX)
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